Abstract
Introduction: Triple-negative breast cancer (TNBC), which lacks expression of estrogen receptor (ER), progesterone receptor (PgR), and epidermal growth factor receptor 2 (HER2), currently has no effective hormonal or molecular target therapy. Objective and Methods: To elucidate the role of the mammalian target of rapamycin (mTOR) signaling pathway in TNBC, the expression of molecules involved in mTOR signaling including mTOR, phosphorylated (p)-mTOR, p-4EBP1, GLUT1, GLUT3, HIF-1α, and Ki67 was investigated by immunohistochemistry in 35 TNBC and 81 non-TNBC cases. Results: Expression of p-mTOR, the activated form of mTOR, but not unphosphorylated mTOR, was significantly higher in non-TNBC cases than in TNBC cases. Expression of p-4EBP1, GLUT1, and GLUT3 was higher in TNBC cases than in non-TNBC cases. When the localization of p-mTOR was classified as nuclear, perinuclear, or cytoplasmic, nuclear localization of p-mTOR was observed more frequently in TNBC than in non-TNBC cases and was correlated with the expression of GLUT1 and GLUT3, which was related to proliferation activity examined with Ki67. Conclusions: mTOR signaling regulates cell proliferation in some cases of TNBC and may be a potential target of molecular therapy for TNBC.
References
1.
Podo
F
, Buydens
LM
, Degani
H
, Hilhorst
R
, Klipp
E
, Gribbestad
IS
, et al.; FEMME Consortium
. Triple-negative breast cancer: present challenges and new perspectives
. Mol Oncol
. 2010
Jun
;4
(3
):209
–29
.
[PubMed]
1574-78912.
Laplante
M
, Sabatini
DM
. mTOR signaling in growth control and disease
. Cell
. 2012
Apr
;149
(2
):274
–93
.
[PubMed]
0092-86743.
Lousberg
L
, Jerusalem
G
. Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer
. Breast Cancer (Auckl)
. 2017
Jan
;10
:239
–52
.
[PubMed]
1178-22344.
Basho
RK
, Gilcrease
M
, Murthy
RK
, Helgason
T
, Karp
DD
, Meric-Bernstam
F
, et al. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab
. JAMA Oncol
. 2017
Apr
;3
(4
):509
–15
.
[PubMed]
2374-24375.
Costa
RL
, Han
HS
, Gradishar
WJ
. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
. Breast Cancer Res Treat
. 2018
Jun
;169
(3
):397
–406
.
[PubMed]
0167-68066.
Holz
MK
, Ballif
BA
, Gygi
SP
, Blenis
J
. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events
. Cell
. 2005
Nov
;123
(4
):569
–80
.
[PubMed]
0092-86747.
Rowinsky
EK
. Targeting the molecular target of rapamycin (mTOR)
. Curr Opin Oncol
. 2004
Nov
;16
(6
):564
–75
.
[PubMed]
1040-87468.
Noh
WC
, Paik
NS
. Translational regulation: a novel target for breast cancer therapy
. J Korean Breast Cancer Soc
. 2003
;6
(1
):8
–14
. 9.
Fingar
DC
, Blenis
J
. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression
. Oncogene
. 2004
Apr
;23
(18
):3151
–71
.
[PubMed]
0950-923210.
Bernardi
R
, Guernah
I
, Jin
D
, Grisendi
S
, Alimonti
A
, Teruya-Feldstein
J
, et al. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR
. Nature
. 2006
Aug
;442
(7104
):779
–85
.
[PubMed]
0028-083611.
Gordan
JD
, Thompson
CB
, Simon
MC
. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation
. Cancer Cell
. 2007
Aug
;12
(2
):108
–13
.
[PubMed]
1535-610812.
Shackelford
DB
, Vasquez
DS
, Corbeil
J
, Wu
S
, Leblanc
M
, Wu
CL
, et al. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome
. Proc Natl Acad Sci USA
. 2009
Jul
;106
(27
):11137
–42
.
[PubMed]
0027-842413.
Yu
J
, Li
J
, Zhang
S
, Xu
X
, Zheng
M
, Jiang
G
, et al. IGF-1 induces hypoxia-inducible factor 1α-mediated GLUT3 expression through PI3K/Akt/mTOR dependent pathways in PC12 cells
. Brain Res
. 2012
Jan
;1430
:18
–24
.
[PubMed]
0006-899314.
Walsh
S
, Flanagan
L
, Quinn
C
, Evoy
D
, McDermott
EW
, Pierce
A
, et al. mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors
. Breast
. 2012
Apr
;21
(2
):178
–82
.
[PubMed]
0960-977615.
Ueng
SH
, Chen
SC
, Chang
YS
, Hsueh
S
, Lin
YC
, Chien
HP
, et al. Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas
. Int J Clin Exp Pathol
. 2012
;5
(8
):806
–13
.
[PubMed]
1936-262516.
Bakarakos
P
, Theohari
I
, Nomikos
A
, Mylona
E
, Papadimitriou
C
, Dimopoulos
AM
, et al. Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas
. Histopathology
. 2010
Jun
;56
(7
):876
–82
.
[PubMed]
0309-016717.
Dunlop
EA
, Tee
AR
. Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms
. Cell Signal
. 2009
Jun
;21
(6
):827
–35
.
[PubMed]
0898-656818.
Kim
JE
, Chen
J
. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation
. Proc Natl Acad Sci USA
. 2000
Dec
;97
(26
):14340
–5
.
[PubMed]
0027-842419.
Vazquez-Martin
A
, Oliveras-Ferraros
C
, Bernadó
L
, López-Bonet
E
, Menendez
JA
. The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells
. Biochem Biophys Res Commun
. 2009
Mar
;380
(3
):638
–43
.
[PubMed]
0006-291X20.
Urruticoechea
A
, Smith
IE
, Dowsett
M
. Proliferation marker Ki-67 in early breast cancer
. J Clin Oncol
. 2005
Oct
;23
(28
):7212
–20
.
[PubMed]
0732-183X21.
Tsuda
H
, Akiyama
F
, Kurosumi
M
, Sakamoto
G
, Watanabe
T
; Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section
. Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy
. Jpn J Clin Oncol
. 1998
Aug
;28
(8
):486
–91
.
[PubMed]
0368-281122.
Elston
CW
, Ellis
IO
. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up
. Histopathology
. 1991
Nov
;19
(5
):403
–10
.
[PubMed]
0309-0167© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
